PD-L1 Antikörper

Produktnummer ABIN7670557

Dieses Anti-PD-L1-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von PD-L1 in ELISA (Capture). Geeignet für Human.

Kurzübersicht für PD-L1 Antikörper (ABIN7670557)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: ELISA (Capture)

Klon: 9B7

Produktdetails anti-PD-L1 Antikörper

Verwendungszweck: PD-L1 Monoclonal Antibody(Capture)

Aufreinigung: Protein A/G Purification

Immunogen: Recombinant Human PD-L1 L1 protein expressed by Mammalian

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA Capture 2-8 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Sterile PBS , pH 7.4

Konservierungsmittel: Without preservative

Handhabung: Avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C Valid for 1 month or -20°C Valid for 12 months

Haltbarkeit: 12 months

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: PD-L1

Hintergrund: CD274,B7H1,PDCD1L1,PDCD1LG1,PDL1,PD-L1,Programmed ceLL death 1 Ligand 1,B7 homoLog 1,PDCD1 Ligand 1,Programmed death Ligand 1,hPD-L1,Plays a critical role in induction and maintenance of immune tolerance to self.As a ligand for the inhibitory receptor PDCD1/PD-1,modulates the activation threshold of T-cells and limits T-cell effector response.Through a yet unknown activating receptor,may costimulate T-cell subsets that predominantly produce interleukin-10 (Il10).Can also act as a transcription coactivator: in response to hypoxia,translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC,leading to pyroptosis.The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system,thereby facilitating tumor survival.The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTls) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response,providing a rationale for cancer immunotherapy.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints